ORIGINAl Article

Usefulness of colestimide for diarrhea in postoperative Crohn’s disease

Aya Hojo,*,†,‡ Taku Kobayashi,*,† Mao Matsubayashi,* Hiromu Morikubo,*† Yusuke Miyatani,* Tomohiro Fukuda,*† Kunio Asonuma,* Shintaro Sagami,*† Masaru Nakano,*† Takahisa Matsuda‡ and Toshifumi Hibi*

*Center for Advanced IBD Research and Treatment, †Department of Gastroenterology and Hepatology, Kitasato University Kitasato Institute Hospital and ‡Division of Gastroenterology and Hepatology, Toho University Omori Medical Center, Tokyo, Japan

Key words
colestimide, Crohn’s disease, diarrhea, ileocecal resection.

Accepted for publication 24 June 2022.

Correspondence
Taku Kobayashi, Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, 5-9-1, Shirokanedai, Minato-ku, Tokyo 108-8642, Japan.
Email: drkobataku@gmail.com

Declaration of conflict of interest: Taku Kobayashi has received research grant from Otsuka Holdings, Abbvie GK, Actvidia, Altres Pharma Corporation, JMDC Inc., Mochida Pharmaceutical, Pfizer, Zeria Pharmaceutical, Nippon Kayaku, JIMRO, Google Asia Pacific, served as a speaker, a consultant or an advisory role for Takeda Pharmaceutical, Actvidia, Alters Pharma Corporation, Zeria Pharmaceutical, Kyorin Pharmaceutical, Nippon Kayaku, Mitsubishi Tanabe Pharma Corporation, Abbvie GK, Pfizer, Janssen, Thermo Fisher Diagnostics, JIMRO, Bristol-Myers Squibb, Gilead Sciences, Eli Lilly, Galapagos, KISSEI Pharmaceutical. Hiromu Morikubo has received research grants from Japan Foundation for Takeda Pharmaceutical, Applied Enzymology. Yusuke Miyatani has served as a speaker of Abbvie; received research funding from Japan Foundation for Applied Enzymology; and as an endowed chair of Abbvie, JIMRO, Zeria Pharmaceutical, Kyorin Pharmaceutical, Mochida Pharmaceutical, Otsuka Holdings, and EA Pharma. Kunio Asonuma has an endowed chair from Abbvie, JIMRO, Zeria Pharmaceutical, Kyorin Pharmaceutical, Mochida Pharmaceutical, EA Pharma. Shintaro Sagami served as a speaker for Abbvie, Takeda Pharmaceutical, Janssen Pharmaceutical, Mitsubishi Tanabe Pharma, Nippon Kayaku, and Zeria Pharmaceutical and as an endowed chair for Abbvie, JIMRO, Zeria Pharmaceutical, Kyorin Pharmaceutical, Mochida Pharmaceutical.

Abstract

Background and Aim: Crohn’s disease (CD) often causes intractable diarrhea after intestinal resection. Anion exchange resins have been reported to be effective in patients with bile acid diarrhea after distal ileectomy; furthermore, bile acid metabolism has been implicated in the pathogenesis of CD. Therefore, we aimed to examine the effectiveness of colestimide in the management of postoperative CD, and to compare its impact between patients with and those without ileocecal resection.

Methods: Postoperative CD patients prescribed colestimide for diarrhea between April 2017 and December 2020 were retrospectively evaluated for changes in the total Crohn’s disease activity index (CDAI), each CDAI component including diarrhea frequency/week, albumin, and C-reactive protein (CRP) was evaluated before and after the administration of colestimide. Furthermore, comprehensive patient and physician assessments were reviewed from medical records during the first outpatient visit as a global clinical judgment after the initiation of colestimide therapy.

Results: A total of 24 patients were included, of whom 17 had a previous history of ileocecal resection. Significant improvement was noted in CDAI and diarrhea frequency only in the ileocecal resection group (CDAI: 114.5 ± 52.7 and 95.4 ± 34.8, P < 0.05; diarrhea frequency/week 23.8 ± 14.1 and 15.4 ± 11.2, P < 0.05, respectively). There was no significant improvement in other CDAI components, albumin level, or CRP level in either group. In the global clinical judgment, 13 and 4 patients in the ileocecal and non-ileocecal resection groups, respectively, were judged as “effective,” with an overall efficacy rate of 70.8%.

Conclusion: Colestimide is effective for diarrhea in patients with postoperative CD, especially after ileocecal resection.
Introduction

Crohn’s disease (CD) is a chronic inflammatory bowel disease with repeated remission and relapse. Diarrhea is one of the major symptoms of CD. It has been reported that approximately 50% of patients with CD require intestinal resection within 5 years and 60% within 10 years due to stenotic and/or perforating disease. Recently, the surgery rate has decreased due to therapeutic advances; however, many patients still require intestinal resection. One of the reasons for the lower quality of life in patients after intestinal resection is postoperative diarrhea, which is reported to occur in 24% of patients after subtotal colectomy and in 79% of patients after ileal resections >10 cm in length. Diarrhea may be dependent or independent of inflammation. One inflammation-independent diarrhea is bile acid diarrhea, which occurs because bile flows into the large intestine due to insufficient absorption of bile in the terminal ileum. It has been reported that anion exchange resins, such as cholestyramine and colestimide, improve bile acid diarrhea by adsorbing bile acids in the gastrointestinal tract, and colesevelam has been shown to be effective in the management of bile acid diarrhea in patients with CD. However, it has been suggested that abnormal metabolism of secondary bile acids produced in the intestinal tract promotes an inflammatory response in the intestinal epithelium and exacerbates the pathogenesis of CD and that resins inhibit intestinal inflammation.

Recently, a secondary bile acid, 3-oxolithocholic acid (3-oxoLCA), was reported to inhibit TH17 cells; moreover, TH17 cell activation due to decreased 3-oxoLCA may be involved in the pathogenesis of CD. Therefore, this study aimed to examine the effectiveness of colestimide in the management of diarrhea in postoperative CD patients and to compare its impact between patients with and those without ileocecal resection.

Methods

Patients. We conducted a retrospective observational study using a prospective database of patients with inflammatory bowel disease at Kitasato University Kitasato Institute Hospital. Patients with CD with a history of bowel surgery who were prescribed colestimide between April 2017 and December 2020 were enrolled. The diagnosis of CD was made clinically, endoscopically, and histologically based on national guidelines. Clinical decisions regarding prescriptions were made by physicians during routine clinical practice. Colestimide was administered in the form of Corebine tablets 500 mg (Mitsubishi Tanabe Pharma Corporation, Osaka, Japan).

Evaluation. Clinical information was extracted from patients’ medical records or the prospective patient database at Kitasato University Kitasato Institute Hospital, where Crohn’s disease activity index (CDAI) is routinely recorded for all patients with...
CD at every visit. The primary endpoint was a change in diarrhea frequency, and the secondary endpoints were changes in CDAI, CDAI components other than diarrhea, C-reactive protein (CRP) level, and albumin level. The global clinical judgment was a comprehensive assessment of the effectiveness of the patient and specialist at the first outpatient visit after the initiation of colestimide therapy, retrospectively determined from the patient's medical record and classified as effective or ineffective. Adverse events were also assessed retrospectively from medical records. Patients were classified according to the presence or absence of a history of ileocecal resection (ileocecal resection group vs non-ileocecal resection group). Endoscopic findings were compared in patients who underwent endoscopy before and after the administration of colestimide without any changes in other treatments.

**Statistical analysis.** The Wilcoxon matched-pair signed-rank test was conducted to analyze the results before and after colestimide administration, and the chi-square test was used to compare the effective and ineffective groups according to the global clinical judgment of effectiveness. GraphPad Prism 8 (GraphPad Software, San Diego, CA, USA) was used for statistical analysis. For all tests, a P-value <0.05 was considered statistically significant, and variables pertaining to accuracy were calculated with a 95% confidence interval (CI).

**Ethical considerations.** The study was conducted in accordance with the Declaration of Helsinki principles and Good Clinical Practice guidelines. The study protocol was approved by the Research Ethics Committee of Kitasato University Kitasato Institute Hospital (Kitasato University Kitasato Institute Hospital approval numbers: 13034, 21069). An opt-out process was used in this study, in which patients were provided with the opportunity to decline their participation based on the information available on the hospital's website.

**Results**

**Patients.** Twenty-four patients with CD with a history of bowel surgery were included in the study (Table 1). Of these, 17 patients had previously undergone ileocecal resection (ileocecal resection group). All seven patients in the non-ileocecal resection group had small bowel resections (ileum 3, jejunum 1, ileum, and jejunum 1, unknown details but did not receive ileocecal resection 2), while all five patients who underwent colorectal resection had a history of ileocecal resection. The number of surgeries in each patient ranged from 1 to 3 (median, 1), with 1 surgery in 15 (62.5%), 2 in 5 (20.8%), and 3 in 4 (16.7%) patients. One patient had a history of cholecystectomy at the commencement of treatment. The dose of colestimide was 1.5–3 g, which was taken three times a day in most patients (median 1.5 ± 0.81).

The average duration of treatment until the first visit was 55.5 ± 25.5 days. Colestimide was administered due to the lack of efficacy of single or combination anti-diarrheal agents in eight patients (47.1%), including six patients with loperamide hydrochloride, three patients with berberine chloride hydrate, two patients with albumin tannate, and one patient with ramocetron hydrochloride.

**Overall effectiveness.** A significant improvement was noted in CDAI (before: 138.8 ± 66.4, after: 115 ± 56.3, P < 0.05) (Table 2) after the administration of colestimide. Only the frequency of diarrhea per week (before: 26.1 ± 16.8, after: 19.7 ± 16.7, P < 0.05) showed a significant reduction among the

| Table 1 | Patient’s characteristics | Total (n = 24) |
|---------|--------------------------|--------------|
| Sex, male, n (%) | 15 (62.5) |
| Age (years), (mean ± SD) | 44.5 ± 11.0 |
| Disease duration (years), (mean ± SD) | 20 ± 10.1 |
| Montreal classification | |
| Age | A1/A2/A3, n (%) | 1 (4.35)/23 (95.8)/0 (0) |
| Location | L1/L2/L3/L4, n (%) | 13 (54.2)/0 (0)/11 (45.8)/0 (0) |
| Behavior | B1/B2/B3/B4, n (%) | 0 (0)/13 (54.2)/11 (45.8)/0 (0) |
| Elemental diet, n (%) | 8 (33.3) |
| Anti-diarrheal drugs, n (%) | 8 (33.3) |
| Anti-TNFα agents, n (%) | 15 (62.5) |
| Thiopurines, n (%) | 10 (41.7) |
| Number of operations | |
| 1/2/3, n (%) | 15 (62.5)/5 (20.8)/4 (16.7) |

| Table 2 | Changes in clinical parameters |
|---------|-------------------------------|
| Oral administration of colestimide | Before | After |
| CDAI | 138.8 ± 66.4 | 115 ± 56.3 |
| Frequency of diarrhea/week | 26.1 ± 16.8 | 19.7 ± 16.7 |
| Frequency of abdominal pain/week | 1.79 ± 2.6 | 0.79 ± 2.23 |
| Albumin (g/dL) | 4.05 ± 0.58 | 4 ± 0.54 |
| CRP (mg/dL) | 0.22 ± 0.42 | 0.44 ± 0.99 |

CDAI, Crohn’s disease activity index; CRP, C-reactive protein.
Comparison by surgical procedure. When assessing effectiveness based on the history of ileocecal resection, significant improvement was observed in CDAI and diarrhea frequency only in the ileocecal resection group (CDAI: 114.5 ± 52.7 and 95.4 ± 34.8, \( P < 0.05 \); frequency of diarrhea/week 23.8 ± 14.1 and 15.4 ± 11.2, \( P < 0.05 \), before and after prescription, respectively) (Table 3, Fig. 1). There was no significant improvement in the other CDAI components and albumin levels. CRP was also not improved either in the ileocecal resection group (before: 0.14 ± 0.27, after: 0.19 ± 0.29, \( P = 0.1304 \)) or in the non-ileocecal resection group (before: 0.42 ± 0.71, after: 1.06 ± 1.86, \( P = 0.7188 \)).

Comparison by global clinical judgment. In a comprehensive evaluation of global clinical judgment, 13 of 17 patients in the ileocecal resection group and four of seven patients in the non-ileocecal resection group were rated as “effective” (the overall efficacy rate was 70.8% [17/24]). None of the baseline factors were significantly associated with effectiveness in all patients (Table 4). In addition, we explored baseline factors predicting effectiveness in the ileocecal resection group separately but found no significant factors (Table 5). Concomitant use of anti-diarrheal agents at baseline did not affect effectiveness (effective, \( n = 6 \); ineffective, \( n = 2 \)).

Endoscopic findings. We compared endoscopic findings in patients whose endoscopy before and after the administration of colestimide without any changes in other treatment was available (\( n = 13 \), mean duration before and after colestimide, 12.2 and 18.8 months, respectively). Only one patient had an active endoscopic lesion at baseline (a simple endoscopic score for Crohn’s disease [SES-CD] of 9). One patient had a worsening of SES-CD from 0 to 3 points, while all other patients (\( n = 12 \)) including a patient with a baseline SES-CD of 9 had no change in SES-CD.

Adverse events. Three patients developed constipation, of whom two patients discontinued treatment, while one continued with dose reduction (from 3 to 2 g per day), and one patient had epigastric pain, which resolved after the cessation of colestimide. The dosage was 3 and 1.5 g per day in two cases of constipation and 1.5 g per day in one case of epigastric pain.

Discussion

This real-world retrospective study examined the clinical usefulness of colestimide in improving diarrhea in postoperative CD patients and found that improvement in diarrhea frequency was
significant only in the ileocecal resection group and that there was no improvement in parameters other than diarrhea frequency.

There are a variety of different types of postoperative diarrhea, including (i) interruption of the ileal brake, which reduces gastric emptying, prolongs small intestinal transit time, and reduces both gastric and pancreatic secretion; (ii) bacterial overgrowth in the small bowel; (iii) diarrhea due to inflammation of CD; (iv) bile acid diarrhea caused by the malabsorption of bile acid in the ileum; and (v) irritable bowel syndrome overlapping with the postoperative condition. The treatment of these conditions includes surgical procedures, dietary therapy, and pharmacotherapy, such as digestive enzymes, vitamins,
The effectiveness of colestimide

Since a reduction in bile acid concentration, higher C4, and lower FGF19 in bile. These reports suggest that bile malabsorption may also occur in patients with CD. The presence of ileal resection group, the effectiveness of bile acid diarrhea following ileocolonic resection seemed to be greater than that caused by CD pathogenesis.

Bile acid diarrhea occurs in 11–14% of patients with CD without a history of intestinal resection. Since a reduction in the expression of sodium-dependent bile transporters in the intestine is reported to cause bile acid diarrhea in CD, it may be efficacious in patients without terminal ileal resection. However, in our study, the reduction in diarrhea frequency was significant only in the ileocolonic resection group, and the effectiveness of bile acid diarrhea following ileocolonic resection seemed to be greater than that caused by CD pathogenesis.

In contrast, some studies have reported that bile acid metabolism is involved in the pathophysiology of CD. The concentration of bile acids in the bile of CD patients is elevated compared with that in healthy individuals, and the production of 7α-hydroxy-4-cholesterin-3-one (C4), a precursor of bile acids, is increased due to the malabsorption of bile acids. In addition, fibroblast growth factor 19 (FGF19), which regulates bile acid synthesis, is decreased in patients with CD. Patients with ileal dysfunction, including those with post-ileocolonic resection or those with active disease in the ileum, are reported to have higher bile acid concentration, higher C4, and lower FGF19 in bile. These reports suggest that bile malabsorption may also occur in patients with CD with the active ileal disease without ileocolonic resection. Most of the patients included in this study had relatively mild inflammation, and further studies are needed to examine the efficacy of colestimide in patients with moderate-to-severe disease.

To the best of our knowledge, no studies have reported the use of bile acid resins after bowel surgeries other than ileocolonic resection. In our study, although there was no change in the frequency of diarrhea in the non-ileocolonic resection group, the presence of a previous history of ileocolonic resection was not a significant factor for effectiveness in the analysis of the global clinical judgment. These results suggest that the presence of a prior history of ileocolonic resection may not be the sole factor and each patient has a different degree of postoperative bile acid malabsorption. It may be interesting to see if an objective assessment of bile acid malabsorption by 75Se-labeled homocholic acid-taurine (75SeHCAT) could predict the efficacy of colestimide.

This study has several limitations. First, due to the retrospective nature of the study, we were unable to obtain sufficient information, such as detailed surgical procedures and the length of the remaining small bowel. However, there was no difference in the effectiveness of colestimide according to the number of previous surgeries. Second, the degree of inflammation before and after administration was not evaluated using objective measures, such as endoscopy. However, in our study, the CDAI was prospectively recorded in our routine practice, which could have minimized the potential bias. Third, because of the small sample size, the statistical power to detect the effectiveness of colestimide was low and multivariate analysis was not possible. Lastly, the anti-inflammatory effect could not be sufficiently examined because most patients had low inflammatory disease activity due to the postsurgical clinical settings. Therefore, larger and well-designed clinical studies are warranted.

In conclusion, colestimide is effective in the management of diarrhea in patients with postoperative CD, especially after ileocolonic resection.

Acknowledgments

The authors are grateful to Tadao Mori, and Toyomi Ishibashi for their assistance in this study.

References

1. Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn’s disease. Lancet. 2017; 389: 1741–55.
2. Munkholm P, Langholz E, Davidsen M, Binder V. Intestinal cancer risk and mortality in patients with Crohn’s disease. Gastroenterology. 1993; 105: 1716–23.
3. Dittrich AE, Sutton RT, Haynes K, Wang H, Fedorak RN, Kroeker KL. Incidence rates for surgery in Crohn’s disease have decreased: a population-based time-trend analysis. Inflamm. Bowel Dis. 2020; 26: 1909–16.
4. Papa MZ, Kami T, Koller M et al. Avoiding diarrhea after subtotal colectomy with primary anastomosis in the treatment of colon cancer. J. Am. Coll. Surg. 1997; 184: 67–9.
5. Yde J, Larsen HM, Laueberg S, Krogh K, Moeller HB. Chronic diarrhoea following surgery for colon cancer—frequency, causes and treatment options. Int. J. Colorectal Dis. 2018; 33: 683–94.
6. Sadowski DC, Camilleri M, Chey WD et al. Canadian Association of Gastroenterology Clinical Practice Guideline on the management of bile acid diarrhea. Clin. Gastroenterol. Hepatol. 2020, 18(1): 24–41.e1.
7. Hofmann AF, Poley JR. Cholestyramine treatment of diarrhea associated with ileal resection. N. Engl. J. Med. 1969; 281: 397–402.
8. Beigel F, Teich N, Howaldt S et al. Colesevelam for the treatment of bile acid malabsorption-associated diarrhea in patients with Crohn’s disease: a randomized, double-blind, placebo-controlled study. J. Crohns Colitis. 2014; 8: 1471–9.
9. Kumar A, Al-Hassi HO, Steed H, Phipps O, Brooks MJ. Bile acids and the microbiome: making sense of this dynamic relationship in their role and management in Crohn’s disease. Can. J. Gastroenterol. Hepatol. 2022; 22: 8416578.
10. Biagioli M, Marchianò S, Carino A et al. Bile acids activated receptors in inflammatory bowel disease. Cell. 2021; 10: 1281.
11. Kriaa A, Mariarou V, Jhabla A et al. Bile acids: key players in inflammatory bowel diseases? Cell. 2022; 11: 901.
12. Duboc H, Rajca S, Ranteau D et al. Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases. Gut. 2013; 62: 531–9.
13. Lee JW, Pliticha D, Hogstrom L et al. Multi-omics reveal microbial determinants impacting responses to biologic therapies in inflammatory bowel disease. Cell Host Microbe. 2021; 29: 1294–1304.e4.
14 Thomas JP, Modos D, Rushbrook SM, Powell N, Korcsmaros T. The emerging role of bile acids in the pathogenesis of inflammatory bowel disease. Front. Immunol. 2022; 3: 829525.
15 Paik D, Yao L, Zhang Y et al. Human gut bacteria produce TH17-modulating bile acid metabolites. Nature. 2022; 603: 907–12.
16 Vitek L. Bile acid malabsorption in inflammatory bowel disease. Inflamm. Bowel Dis. 2015; 21: 476–83.
17 Best WR, Becktel JM, Singleton JW, Kern F. Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study. Gastroenterology. 1976; 70: 439–44.
18 Van Citters GW, Lin HC. Ileal brake: neuropeptidergic control of intestinal transit. Curr. Gastroenterol. Rep. 2006; 8: 367–73.
19 Grace E, Shaw C, Whelan K, Andreyev HJN. Review article: small intestinal bacterial overgrowth – prevalence, clinical features, current and developing diagnostic tests, and treatment. Aliment. Pharmacol. Ther. 2013; 38: 674–88.
20 Barkun A, Love J, Gould M, Pluta H, Steinhart AH. Bile acid malabsorption in chronic inflammatory bowel disease: pathophysiology and treatment. Can. J. Gastroenterol. 2013; 27: 653–9.
21 Borghede MK, Schlüter JM, Agnholt JS, Christensen LA, Gormsen LC, Dahlerup JF. Bile acid malabsorption investigated by selenium-75-homocholic acid taurine (75SeHCAT) scans: causes and treatment responses to cholestyramine in 298 patients with chronic watery diarrhea. Eur. J. Intern. Med. 2011; 22: e137–40.
22 Lenicek M, Duricova D, Komarek V et al. Bile acid malabsorption in inflammatory bowel disease: assessment by serum markers. Inflamm. Bowel Dis. 2011; 17: 1322–7.
23 Jung D, Fantin AC, Scheurer U, Fried M, Kullak-Ublick GA. Human ileal bile acid transporter gene ASBT (SLC10A2) is transactivated by the glucocorticoid receptor. Gut. 2004; 53: 78–84.
24 Pattat R, Duijvestein M, Vande Casteele N et al. Serum concentrations of 7α-hydroxy-4-cholesten-3-one are associated with bile acid diarrhea in patients with Crohn’s disease. Clin. Gastroenterol. Hepatol. 2019; 17: 2722–2730.e4.
25 Nolan JD, Johnston IM, Pattini SS, Dew T, Orchard TR, Walters JR. Diarrhea in Crohn’s disease: investigating the role of the ileal hormone fibroblast growth factor 19. J. Crohns Colitis. 2015; 9: 125–31.
26 Wedlake L, A’hem R, Russell D, Thomas K, JRF W, HIN A. Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome. Aliment. Pharmacol. Ther. 2009; 30: 707–17.